[go: up one dir, main page]

AR088921A2 - PROCESO PARA LA PREPARACION DE DERIVADOS DE ACETILENO QUE TIENEN ACTIVIDAD ANTAGONISTA mGluR5, COMPOSICIONES Y USO DE LOS COMPUESTOS - Google Patents

PROCESO PARA LA PREPARACION DE DERIVADOS DE ACETILENO QUE TIENEN ACTIVIDAD ANTAGONISTA mGluR5, COMPOSICIONES Y USO DE LOS COMPUESTOS

Info

Publication number
AR088921A2
AR088921A2 ARP120104356A ARP120104356A AR088921A2 AR 088921 A2 AR088921 A2 AR 088921A2 AR P120104356 A ARP120104356 A AR P120104356A AR P120104356 A ARP120104356 A AR P120104356A AR 088921 A2 AR088921 A2 AR 088921A2
Authority
AR
Argentina
Prior art keywords
hydrogen
alkyl
formula
compound
preparation
Prior art date
Application number
ARP120104356A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9926969&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR088921(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR088921A2 publication Critical patent/AR088921A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/24—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/16—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/23—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
    • C07D215/08—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms with acylated ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

Proceso para la preparación de derivados de acetileno que tienen actividad antagonista mGIuR5. Composición farmacéutica que lo comprende. Reivindicación 1: Un proceso para la preparación de un compuesto de la fórmula (1), en la que: m es 0 ó 1; n es 0 ó 1; y A es hidroxi; X es hidrógeno, e Y es hidrógeno; o A forma una ligadura simple con X o con Y; R⁰ es hidrógeno, alquilo C₁₋₄, alcoxi C₁₋₄, trifluorometilo, halógeno, ciano, nitro, -COOR¹; donde R¹ es alquilo C₁₋₄, o -COR², donde R² es hidrógeno o alquilo C₁₋₄; y R es -COR³, -COOR³, -CONR⁴R⁵ ó -SO₂R⁶; donde R³ es alquilo C₁₋₄, cicloalquilo C₃₋₇ o fenilo opcionalmente sustituido, 2-piridilo o 2-tienilo; R⁴ y R⁵, independientemente, son hidrógeno o alquilo C₁₋₄ y R⁶ es alquilo C₁₋₄, cicloalquilo C₃₋₇ o fenilo opcionalmente sustituido; R es hidrógeno o alquilo C₁₋₄; y R es hidrógeno o alquilo C₁₋₄; o R y R forman juntos un grupo -CH₂(CH₂)ₚ-; donde p es 0, 1 ó 2; en cuyo caso uno de n y p es diferente de 0; a condición de que R⁰ sea diferente de hidrógeno, trifluorometilo y metoxi cuando m es 1, n es 0, A es hidroxi, X e Y son ambos hidrógeno, R es COOEt y R y R forman juntos un grupo -(CH₂)₂-; en forma de base libre o de una sal de adición de ácido, caracterizado porque comprende el paso de: a) para la producción de un compuesto de la fórmula (1), en la que A es hidroxi, hacer reaccionar un compuesto de la fórmula (2) en la que m, n, R, R y R son como se definió en la reivindicación 1, con un compuesto de la fórmula (3) en la que R⁰ es como se definió en la reivindicación 1; o b) para la producción de un compuesto de la fórmula (1) en el que A forma una ligadura simple con X o con Y, deshidratar un compuesto de la fórmula (1) en la que A es hidroxi; y recuperar el compuesto resultante de la fórmula (1), en forma de la base libre o de una sal de adición de ácido.
ARP120104356A 2001-12-04 2012-11-20 PROCESO PARA LA PREPARACION DE DERIVADOS DE ACETILENO QUE TIENEN ACTIVIDAD ANTAGONISTA mGluR5, COMPOSICIONES Y USO DE LOS COMPUESTOS AR088921A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0128996.6A GB0128996D0 (en) 2001-12-04 2001-12-04 Organic compounds

Publications (1)

Publication Number Publication Date
AR088921A2 true AR088921A2 (es) 2014-07-16

Family

ID=9926969

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP020104641A AR037682A1 (es) 2001-12-04 2002-12-02 Derivados de acetileno que tienen actividad antagonista para receptores glutamato metabotropico humanos, composicion farmaceutica, una combinacion y el uso de dichos derivados para la fabricacion de composiciones farmaceuticas
ARP120104356A AR088921A2 (es) 2001-12-04 2012-11-20 PROCESO PARA LA PREPARACION DE DERIVADOS DE ACETILENO QUE TIENEN ACTIVIDAD ANTAGONISTA mGluR5, COMPOSICIONES Y USO DE LOS COMPUESTOS

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP020104641A AR037682A1 (es) 2001-12-04 2002-12-02 Derivados de acetileno que tienen actividad antagonista para receptores glutamato metabotropico humanos, composicion farmaceutica, una combinacion y el uso de dichos derivados para la fabricacion de composiciones farmaceuticas

Country Status (31)

Country Link
US (4) US7348353B2 (es)
EP (1) EP1453512B8 (es)
JP (2) JP4176020B2 (es)
KR (2) KR100959204B1 (es)
CN (2) CN100430059C (es)
AR (2) AR037682A1 (es)
AT (1) ATE327755T1 (es)
AU (1) AU2002358585B2 (es)
BR (1) BR0214666A (es)
CA (1) CA2466560C (es)
CO (1) CO5590929A2 (es)
CY (1) CY1105460T1 (es)
DE (1) DE60211944T2 (es)
DK (1) DK1453512T3 (es)
EC (1) ECSP045139A (es)
EG (1) EG24936A (es)
ES (1) ES2263842T3 (es)
GB (1) GB0128996D0 (es)
HU (1) HU229429B1 (es)
IL (1) IL161990A0 (es)
MX (1) MXPA04005456A (es)
MY (1) MY137774A (es)
NO (1) NO327005B1 (es)
NZ (1) NZ533266A (es)
PE (1) PE20030640A1 (es)
PL (1) PL212996B1 (es)
PT (1) PT1453512E (es)
RU (1) RU2341515C2 (es)
TW (1) TWI328578B (es)
WO (1) WO2003047581A1 (es)
ZA (1) ZA200403713B (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0128996D0 (en) 2001-12-04 2002-01-23 Novartis Ag Organic compounds
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
GB0325956D0 (en) * 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
US20080125403A1 (en) 2004-04-02 2008-05-29 Merck & Co., Inc. Method of Treating Men with Metabolic and Anthropometric Disorders
GB0503646D0 (en) * 2005-02-22 2005-03-30 Novartis Ag Organic compounds
GB0508319D0 (en) 2005-04-25 2005-06-01 Novartis Ag Organic compounds
GB0508318D0 (en) * 2005-04-25 2005-06-01 Novartis Ag Organic compounds
GB0508314D0 (en) * 2005-04-25 2005-06-01 Novartis Ag Organic compounds
GB0514296D0 (en) * 2005-07-12 2005-08-17 Novartis Ag Organic compounds
AU2007296964B2 (en) 2006-09-11 2012-05-31 Novartis Ag Nicotinic acid derivatives as modulators of metabotropic glutanate receptors
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP2170930B3 (en) 2007-06-04 2013-10-02 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
SG185293A1 (en) * 2007-10-12 2012-11-29 Novartis Ag Organic compounds
AU2012254934B2 (en) * 2007-10-12 2013-10-17 Novartis Ag Metabotropic glutamate receptor modulators for the treatment of Parkinson's disease
JP2011522828A (ja) 2008-06-04 2011-08-04 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
US8703809B2 (en) * 2008-06-30 2014-04-22 Novartis Ag Combination products
ES2547269T3 (es) * 2008-08-12 2015-10-05 Novartis Ag Procedimientos para la preparación de éster metílico de ácido 4-oxo-octahidro-indol-1-carboxílico y derivados del mismo
US8334287B2 (en) 2009-07-17 2012-12-18 Hoffmann-La Roche Inc. Imidazoles
JP2012533601A (ja) 2009-07-23 2012-12-27 ノバルティス アーゲー 運動失調症の処置または予防のための、アザビシクロアルキル誘導体またはピロリジン−２−オン誘導体の使用
TWI558398B (zh) 2009-09-22 2016-11-21 諾華公司 菸鹼乙醯膽鹼受體α７活化劑之用途
WO2011048150A1 (en) 2009-10-20 2011-04-28 Novartis Ag Use of 1h-quinazoline-2,4-diones
PE20130213A1 (es) 2010-04-30 2013-03-19 Novartis Ag Marcadores predictivos utiles en el tratamiento del sindrome fragil x (fxs)
US20130096145A1 (en) 2010-06-24 2013-04-18 Novartis Ag Use of 1H-quinazoline-2,4-diones
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
WO2012084873A1 (en) 2010-12-20 2012-06-28 Novartis Ag 4- (hetero) aryl - ethynyl - octahydro - indole - 1 - carboxylic acid esters
US9067881B2 (en) 2011-01-24 2015-06-30 Novartis Ag 4-tolyl-ethynyl-octahydro-indole-1-ester derivatives
KR20140003580A (ko) 2011-01-27 2014-01-09 노파르티스 아게 니코틴성 아세틸콜린 수용체 알파 7 활성화제의 용도
EP2685977A1 (en) 2011-03-18 2014-01-22 Novartis AG COMBINATIONS OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATORS AND mGluR5 ANTAGONISTS FOR USE IN DOPAMINE INDUCED DYSKINESIA IN PARKINSON'S DISEASE
AU2011376333A1 (en) 2011-09-07 2014-03-13 Novartis Ag Use of 1H-quinazoline- 2, 4 -diones for use in the prevention or treatment photosensitive epilepsy
WO2013131981A1 (en) 2012-03-08 2013-09-12 Novartis Ag Predictive markers useful in the diagnosis and treatment of fragile x syndrome (fxs)
GB201215033D0 (en) 2012-08-23 2012-10-10 Novartis Ag Diazepinone derivatives
MX362819B (es) 2013-01-15 2019-02-18 Novartis Ag Uso de agonistas del receptor nicotinico de acetilcolina alfa 7 para el tratamiento de la narcolepsia.
CN105246485B (zh) 2013-01-15 2019-03-15 诺华有限公司 α7烟碱型乙酰胆碱受体激动剂的应用
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
RS65632B1 (sr) 2013-06-05 2024-07-31 Bausch Health Ireland Ltd Ultra-prečišćeni agonisti guanilat-ciklaze c, postupak njihove pripreme i upotrebe
PT3007682T (pt) 2013-06-12 2017-11-02 Novartis Ag Formulação de libertação modificada
GB201312800D0 (en) 2013-07-17 2013-08-28 Heptares Therapeutics Ltd mGlu5 modulators
CN105669686B (zh) * 2014-11-19 2018-08-03 上海合全药业股份有限公司 一种6-(叔丁氧羰基)八氢呋喃[2,3-c]吡啶-4-羧酸的合成方法
KR20250048143A (ko) 2017-07-31 2025-04-07 노파르티스 아게 코카인 사용 감소 또는 코카인 사용 재발 예방에 있어서 마보글루란트의 용도
CN110891564A (zh) 2017-07-31 2020-03-17 诺华股份有限公司 玛沃谷兰在减少酒精使用或在预防复用酒精中的用途
US20220175793A1 (en) * 2019-01-29 2022-06-09 Novartis Ag The use of an mglur5 antagonist for treating opioid analgesic tolerance
EP4007575B1 (en) * 2019-11-05 2023-09-27 Claes THULIN 4-[5-[(rac)-1-[5-(3-chlorophenyl)-3-isoxazolyl]ethoxy]-4-methyl-4h-1,2,4-triazol-3-yl]pyridine for use in prevention and/or treatment of stress
EP4181918A2 (en) * 2020-07-17 2023-05-24 Novartis AG Mavoglurant, a mglur5 antagonist, for use in the treatment in the reduction of opioid use
US20240050408A1 (en) 2020-12-11 2024-02-15 Novartis Ag Use of mglur5 antagonists for treating amphetamine addiction
CA3204360A1 (en) 2020-12-14 2022-06-23 Novartis Ag Use of mglur5 antagonists for treating gambling disorder

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2741009A1 (de) * 1976-09-22 1978-03-23 Sandoz Ag 4-styryl-4-indolinol-derivate, ihre verwendung und herstellung
DE2802833A1 (de) 1978-01-23 1979-07-26 Sandoz Ag 4-styryl-4-indolinol-derivate, ihre verwendung und herstellung
US5264456A (en) 1989-12-29 1993-11-23 Allergan, Inc. Acetylenes disubstituted with a furyl group and a substituted phenyl group having retinoid like activity
US5284957A (en) 1992-09-03 1994-02-08 Eli Lilly And Company Excitatory amino acid receptor antagonists
US5593994A (en) 1994-09-29 1997-01-14 The Dupont Merck Pharmaceutical Company Prostaglandin synthase inhibitors
WO1997008133A1 (fr) 1995-08-22 1997-03-06 Japan Tobacco Inc. Composes amide et leur utilisation
EP0934307B1 (en) 1996-06-19 2011-04-27 Aventis Pharma Limited Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase
TW544448B (en) * 1997-07-11 2003-08-01 Novartis Ag Pyridine derivatives
DE69915472T2 (de) 1998-06-04 2004-08-19 Kumiai Chemical Industry Co., Ltd. Phenylacetylenderivate und bakterizide für landwirtschaft und gartenbau
WO2000020001A1 (en) 1998-10-02 2000-04-13 Novartis Ag Mglur5 antagonists for the treatment of pain and anxiety
CZ20014488A3 (cs) 1999-07-06 2003-01-15 Eli Lilly And Company Selektivní antagonisté iGluR5 receptoru pro léčení migrény
GB0007108D0 (en) 2000-03-23 2000-05-17 Novartis Ag Organic compounds
IL155202A0 (en) 2000-10-20 2003-11-23 Biocryst Pharm Inc Biaryl compounds as serine protease inhibitors
CZ20031795A3 (cs) 2000-12-04 2004-01-14 F. Hoffmann-La Roche Ag Fenylethenylové nebo fenylethynylové deriváty jako antagonisté glutamátového receptoru
GB0103045D0 (en) 2001-02-07 2001-03-21 Novartis Ag Organic Compounds
US7138404B2 (en) 2001-05-23 2006-11-21 Hoffmann-La Roche Inc. 4-aminopyrimidine derivatives
TW200303309A (en) 2001-12-04 2003-09-01 Bristol Myers Squibb Co Novel n-[4-(1h-imidazol-1-yl)-2-fluorophenyl]-3-trifluoromethyl)-1h-pyrazole-5-carboxamides as factor Xa inhibitors
GB0128996D0 (en) * 2001-12-04 2002-01-23 Novartis Ag Organic compounds
DE60219068T2 (de) 2001-12-04 2007-12-13 F. Hoffmann-La Roche Ag Substituierte 2-amino-cykloalkankarboxamide und ihre verwendung als cysteinprotease-inhibitoren

Also Published As

Publication number Publication date
CN101366714B (zh) 2014-09-17
KR20100020044A (ko) 2010-02-19
DE60211944D1 (de) 2006-07-06
ATE327755T1 (de) 2006-06-15
IL161990A0 (en) 2005-11-20
BR0214666A (pt) 2004-11-03
RU2341515C2 (ru) 2008-12-20
MXPA04005456A (es) 2004-10-11
US20080146647A1 (en) 2008-06-19
HU229429B1 (en) 2013-12-30
CA2466560A1 (en) 2003-06-12
US20120010263A1 (en) 2012-01-12
US8536229B2 (en) 2013-09-17
CO5590929A2 (es) 2005-12-30
ECSP045139A (es) 2004-07-23
CN1592623A (zh) 2005-03-09
AU2002358585A1 (en) 2003-06-17
CA2466560C (en) 2010-07-27
DK1453512T3 (da) 2006-08-28
PL368739A1 (en) 2005-04-04
AU2002358585B2 (en) 2006-01-19
CN101366714A (zh) 2009-02-18
HUP0402191A3 (en) 2010-03-29
CY1105460T1 (el) 2010-04-28
EP1453512A1 (en) 2004-09-08
JP2005514381A (ja) 2005-05-19
AR037682A1 (es) 2004-12-01
TW200304910A (en) 2003-10-16
NO20042673L (no) 2004-06-25
WO2003047581A1 (en) 2003-06-12
JP5036648B2 (ja) 2012-09-26
NZ533266A (en) 2005-02-25
CN100430059C (zh) 2008-11-05
EP1453512B8 (en) 2006-07-19
PT1453512E (pt) 2006-10-31
JP4176020B2 (ja) 2008-11-05
US7348353B2 (en) 2008-03-25
KR100959204B1 (ko) 2010-05-19
HUP0402191A2 (hu) 2005-02-28
ES2263842T3 (es) 2006-12-16
NO327005B1 (no) 2009-04-06
ZA200403713B (en) 2005-10-26
US20050065191A1 (en) 2005-03-24
GB0128996D0 (en) 2002-01-23
JP2008303226A (ja) 2008-12-18
US20130331568A1 (en) 2013-12-12
EG24936A (en) 2011-01-11
PE20030640A1 (es) 2003-09-12
HK1071510A1 (en) 2005-07-22
PL212996B1 (pl) 2012-12-31
KR20050044657A (ko) 2005-05-12
TWI328578B (en) 2010-08-11
DE60211944T2 (de) 2007-05-16
EP1453512B1 (en) 2006-05-31
MY137774A (en) 2009-03-31
RU2004120781A (ru) 2006-01-10
KR100980901B1 (ko) 2010-09-07

Similar Documents

Publication Publication Date Title
AR088921A2 (es) PROCESO PARA LA PREPARACION DE DERIVADOS DE ACETILENO QUE TIENEN ACTIVIDAD ANTAGONISTA mGluR5, COMPOSICIONES Y USO DE LOS COMPUESTOS
AR049443A1 (es) Derivados de pirrolpiridinas
AR034792A1 (es) Derivados de 1-fenilsulfonil-1,3-dihidro-2h-indol-2-ona, su preparacion y su aplicacion en terapeutica
BR0313341A (pt) Método para a preparação de uma oxazinona fundida e método para a preparação de um composto de fórmula iii
EA200300619A1 (ru) Серотонинергические средства
AR046394A1 (es) Derivados de quinolinas y quinazolinas, metodo de preparacion de los mismos y composiciones farmaceuticas que los contienen.
NO20070122L (no) Quinazolinonderivater anvendelige som vanilloidantagonister
EA200200628A1 (ru) Новые производные 1,3-дигидро-2н-индол-2-она и их применение в качестве лигандов рецепторов аргинин-вазопрессина v1b и v1a
WO2008087611A3 (en) Pyrrolidine- and piperidine- bis-amide derivatives
HRP20090162T1 (en) Quinolinone-carboxamide compounds as 5-ht4 receptor agonists
ECSP045078A (es) Tiofen- y tiazolsulfonamidas como agentes antineoplásicos
MEP24208A (en) Derivatives of dioxane-2-alkyl carbamates, preparation method thereof and application of same in therapeutics
ATE340795T1 (de) Benzolsulfonsäureester-indol-5-yl als 5-ht6 rezeptor-antagonisten
BR9809652A (pt) Derivados de quinolina-4-carboxamida como antagonistas de receptor nk-2 e nk-3
CO5601021A2 (es) Derivados de quinazolinona, composiciones farmaceuticas que los contienen y su proceso de preparacion y su uso como antagonistas cb
ATE411287T1 (de) Neue metallproteinaseinhibitoren
AR052915A1 (es) Derivados de pirrolidin y piperidin acetileno
HRP20080027T3 (hr) 4-hidroksi-4-metil-piperidin-1-karboksilna kiselina (4-metoksi-7-morfolin-4-il-benzotiazol-2-il)-amid
EA200100090A2 (ru) Новые пиперидин-4-сульфонамидные производные, способ их получения и содержащие их фармацевтические композиции
AR116906A1 (es) Derivados de heteroarilo bicíclico
NI200900217A (es) Derivados de sulfonil-quinolina
EA200300926A1 (ru) Новый способ промышленного синтеза метил дисложного эфира 5-амино-3-карбоксиметил-4-циано-2-тиофенкарбоновой кислоты и применение для синтеза бивалентных солей ранелиновой кислоты и их гидратов
BR0114753A (pt) Processo para a preparação de compostos de bis-benzazolila
MXPA04006201A (es) Sulfonamidas que contienen fenilo sustituido con grupos heterociclicos, inhibidores de la proteasa del vih de amplio espectro.
DE60106421D1 (de) Hydrate und kristalle einer neuraminsäureverbindung

Legal Events

Date Code Title Description
FC Refusal